Ergoteles’s Harvard Bioscience HBIO Stock Holding History

Ergoteles’s Portfolio HBIO Stock Details HBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-4,884	Closed	-$135K	–	1448
2022 Q4	$135K	Sell	4,884 -9,871	-67%	-$243K	0.01%	1169
2022 Q3	$378K	Sell	14,755 -635	-4%	-$21K	0.01%	874
2022 Q2	$554K	Buy	+15,390	New	+$695K	0.02%	796

Other funds holding HBIO

272 Capital Dallas, Texas $40M AUM 150.07% 1-Year Est. Return

PAIM

Punch & Associates Investment Management Edina, Minnesota $1.73B AUM 27.65% 1-Year Est. Return

Harvey Partners Tarrytown, New York $1.26B AUM 64.44% 1-Year Est. Return

AMH Equity Great Neck, New York $80.3M AUM 78.34% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

ACM

Archon Capital Management Seattle, Washington $177M AUM 108.05% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Ergoteles's HBIO Position: Q1 2023 in Review

Ergoteles sold out of Harvard Bioscience (HBIO) in Q1 2023, closing a stake of 4,884 shares — an estimated $135K sold.

Ergoteles first reported a position in HBIO in Q2 2022 and held it in 3 quarters. The position peaked at $554K in Q2 2022. 65 funds tracked by Wall St. Rank hold HBIO as of Q1 2023.

Ergoteles reported no remaining Harvard Bioscience position as of Q1 2023 after selling out during the quarter.
Ergoteles sold 4,884 Harvard Bioscience shares in Q1 2023, an estimated $135K.
Ergoteles first reported a position in Harvard Bioscience in Q2 2022 and held it in 3 quarters.
Ergoteles's Harvard Bioscience position peaked at $554K in Q2 2022.
65 funds tracked by Wall St. Rank held Harvard Bioscience as of Q1 2023.

Based on Ergoteles's 13F filing for Q1 2023, filed 10 May 2023.